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OBJECTIVE: Obstructive sleep apnea is characterized by increased upper airway collapsibility during sleep. The
present study investigated the use of the negative expiratory pressure test as a method to rule out obstructive sleep
apnea.
METHODS: Flow limitation was evaluated in 155 subjects. All subjects underwent a diurnal negative expiratory
pressure test and a nocturnal sleep study. The severity of sleep apnea was determined based on the apnea-
hypopnea index. Flow limitation was assessed by computing the exhaled volume at 0.2, 0.5, and 1.0 s (V0.2, V0.5, and
V1.0, respectively) during the application of a negative expiratory pressure and expressed as a percentage of the
previous exhaled volume. Receiver-operating characteristic curves were constructed to identify the optimal
threshold volume at 0.2, 0.5, and 1.0 s for obstructive sleep apnea detection.
RESULTS: Mean expiratory volumes at 0.2 and 0.5 s were statistically higher (p,0.01) in healthy subjects than in all
obstructive sleep apneic groups. Increasing disease severity was associated with lower expiratory volumes. The V0.2
(%) predictive parameters for the detection of sleep apnea were sensitivity (81.1%), specificity (93.1%), PPV (98.1%),
and NPV (52.9%). Sensitivity and NPV were 96.9% and 93.2%, respectively, for moderate-to-severe obstructive sleep
apnea, and both were 100% for severe obstructive sleep apnea.
CONCLUSION: Flow limitation measurement by V0.2 (%) during wakefulness may be a very reliable method to
identify obstructive sleep apnea when the test is positive and could reliably exclude moderate and severe
obstructive sleep apnea when the test is negative. The negative expiratory pressure test appears to be a useful
screening test for suspected obstructive sleep apnea.
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INTRODUCTION
Obstructive sleep apnea (OSA) is a risk factor for serious
health problems, such as cardiovascular disease1 and
postoperative complications,2 and could have consequences
for the safety of subjects because of decreased physical
abilities.3-5 The under-recognition of OSA may result in
important health and social costs6 and reduce the quality of
life of affected individuals.7 Obstructive sleep apnea is a
disorder characterized by repetitive episodes of upper
airway closure during sleep, and increased upper airway
collapsibility is one of its main determinants.8
Studies have estimated that OSA, which is defined
based on an apnea-hypopnea index of 5 and excessive
daytime somnolence, may affect at least 2–4% of the
middle-aged general population.9 Interestingly, preva-
lence estimates are much higher when individuals are
divided based on demographic variables, such as age,
sex, and body mass index (BMI).10 In certain subgroups of
the population, such as obese subjects10-11 and profes-
sional drivers,12 the prevalence of OSA may be higher
than in the general population. OSA diagnostic proce-
dures are expensive and time consuming, and studies
have estimated that nearly 80% of men and 93% of
women with moderate-to-severe sleep apnea are undiag-
nosed.13
Although effective screening procedures could help in
evaluating OSA risk, current screening criteria remain
unsatisfactory. The identification of simple, noninvasive,
predictive, and reliable tools to detect OSA would be useful
in several fields.
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Negative expiratory pressure (NEP) is a noninvasive tool
that was initially designed to evaluate flow limitation in
patients with obstructive lung disease; however, Koulouris
and coworkers have suggested that the flow limitation
induced by the NEP application may also reflect upper
airway collapsibility.14 NEP has been applied in subjects
with obesity and/or OSA15-22 to evaluate whether NEP
responses could predict OSA, and the results have been
variable. Some studies15-20 have found that NEP flow-
volume curves and quantitative indices during wakefulness
are useful in the detection of upper airway collapsibility,
whereas other studies21-22 have showed that the NEP
technique appears to have limited usefulness as a clinical
tool for the routine screening of OSA patients during
wakefulness. The difference between these results could be
related to the various flow-limitation measurements that
were applied. Effective screening procedures could help to
distinguish subjects with different probabilities of being
affected by OSA. We have previously demonstrated the
effectiveness of the NEP test in identifying increased upper
airway collapsibility during tidal expiration in severe OSA
patients.23 The aim of the present study was to evaluate
whether the flow limitation induced by NEP during
wakefulness could be a valuable method to detect subjects
with mild or moderate OSA.
MATERIALS AND METHODS
The present study included 155 subjects (130 males and 25
females) who were referred to our sleep laboratory (we
evaluated spirometry to exclude subjects with bronchial
obstruction from the study). Patients with major cranio-
facial or upper airway abnormalities and/or acute or known
chronic pulmonary or neuromuscular disease were
excluded from the study. The mean age of the subjects
was 51¡11 years, and the mean BMI was 32.6¡7.1 kg/m2
(the BMI was $30 for 58.7% of the subjects). Pulmonary
function tests were performed during the day using a
MEDGRAPHICS E´lite plethysmograph (MEDGRAPHICS
Corporation; St. Paul, Minnesota, USA). Each patient gave
informed consent, and the study protocol was approved by
the local ethical committee. All subjects underwent a
diurnal NEP test and nocturnal monitoring using a portable
cardio-respiratory system.24
Nocturnal monitoring was performed using a port-
able computerized system (Somte` Compumedics Inc.;
Abbotsford, VIC, Australia). The recorded signals were
airflow, snoring, thoracic effort, abdominal effort, limb
movement, body position, electrocardiogram, arterial oxy-
gen saturation, pulse rate, and pulse waveform. All were
recorded for at least 6 h.
Polygraphic recordings were analyzed manually by
scorers who were blinded to the results of the NEP test.
Apneas were defined based on the lack of airflow or a.90%
reduction in the airflow signal for at least 10 s. Hypopneas
were defined based on a discernible drop in flow by $30%
of the baseline value for a period lasting at least 10 s,
followed by a $4% drop in SaO2.
25 The apnea-hypopnea
index (AHI) was calculated as the total number of apneas
and hypopneas per hour of estimated total sleep time.
Subjects with an AHI$5 were classified as having OSA, and
subjects with an AHI ,5 were classified as healthy. OSA
severity was determined based on the AHI as mild (5# AHI
,15), moderate (15# AHI #30), or severe (AHI .30).
NEP test
NEP tests were performed in awake subjects at -10 cm
H2O during the morning before the portable home monitor
testing session. The NEP tests were performed while
patients were in the sitting position with the neck in a
neutral position and quietly breathing. All subjects were
wearing a nose clip. The NEP test was performed as
previously described.23 A Super Air Amplifier (Exair model
120021 Cincinnati, Ohio, USA) was able to generate a range
of negative pressures as compressed air was delivered
through the device. Air was supplied by a tank of
compressed air and controlled using an electrically operated
solenoid valve (Norgren Ltd model 95004, Warwickshire,
UK). The solenoid was automatically activated during early
tidal expiration and kept open for 2 s by software control.
The Super Air Amplifier device was placed at the distal
end of a pneumotachograph (Hans Rudolph model 3830;
Kansas City, MO, USA), and mouth pressure was measured
using a pressure transducer (PCLA0050, Sensortechnics
GmbH, Puchheim, D). The signals recorded by the
pneumotachograph and the mouth pressure transducer
were filtered and digitized at 200 Hz. The volume was
obtained by numerically integrating the airflow signal.
Airflow and mouth pressure were displayed in real time
on the computer screen and recorded for subsequent
analysis. Signal analysis and solenoid valve control were
performed using software developed in our laboratory
using LabVIEW 8.2 (National Instruments; Austin, TX,
USA).
The NEP of –10 cm H2O was set by occluding the
pneumotachograph with a stopper and adjusting the flow
of the compressed air to the air amplifier. NEP application
during tidal expiration could produce a sudden and
variable flow reduction that was dependent on upper
airway narrowing. Flow limitation was evaluated by
measuring the expired volume at 0.2, 0.5, and 1.0 s (V0.2,
V0.5, and V1.0, respectively) immediately after NEP applica-
tion (Figure 1). We waited for at least four regular breaths
(as observed by visual inspection of the flow signal on the
computer screen) between consecutive NEP applications.
All subjects underwent seven NEP applications, and a
minimum of four valid measures of expiratory volumes at
0.2, 0.5, and 1.0 s were averaged for each subject. These
values were expressed as the percent of the mean expiratory
volumes of the three breaths preceding each NEP applica-
tion. Measured volumes at 0.2, 0.5, and 1.0 s were only
accepted under regular breathing conditions (i.e., the
differences between inspiratory and expiratory volumes
for each of the three breaths before each NEP application
were less than 10%).
Statistical analysis
Data are reported as means¡SD. A p-value of ,0.05 was
considered significant. Differences between healthy and
OSA subjects with different severity were evaluated using
the Tukey-Kramer test. Logistic regression for the analysis
of continuous factors with categorical responses was
applied. Receiver-operating characteristic (ROC) curves
were constructed to determine the optimal V0.2 (%), V0.5
(%), and V1.0 (%) threshold values for OSA detection. We
also calculated sensitivity, specificity, and positive (PPV)
and negative predictive values (NPV) at various levels of
the measured volumes. A ROC curve was also constructed
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for BMI. Statistical analysis was performed using the
commercial software JMP 8.0.1 (SAS Institute Inc., Cary,
NC, USA).
RESULTS
All subjects had normal forced expiratory flow volume
loops (FVC 99¡16%, FEV1 99¡16%, and FEF25-75 88¡27%
of the predicted values, respectively).
The entire spectrum of OSA severity was represented in
the study population. Nocturnal monitoring showed a mean
AHI of 32¡28 events/h in the study population.
Table 1 shows the anthropometric and respiratory
characteristics of the healthy and OSA subjects with
different degrees of severity.
The mean NEP test results for V0.2 (%), V0.5 (%), and V1.0
(%) in the study population were 19.4¡12.2%, 56.4¡29.9%
and 100.4¡46.0%, respectively. The relationships between
AHI and V0.2 (%), V0.5 (%), and V1.0 (%) are shown in
Figure 2.
Figure 3 shows the mean expiratory volumes at V0.2 (%),
V0.5 (%), and V1.0 (%) for the healthy subjects and the
subjects in the three different OSA severity groups. Exhaled
V0.2 (%) and V0.5 (%) volumes were significantly lower
(p,0.01) in all OSA severity groups, than in healthy
subjects. The exhaled V1.0 (%) volume, however, was only
significant for the healthy subjects compared with the
moderate and severe OSA subjects. The expiratory volumes
were associated with disease severity (i.e., the expiratory
volume decreased as disease severity increased), and the
highest volumes were found in the healthy subjects.
A ROC curve analysis was applied to evaluate the
predictive effectiveness of V0.2 (%), V0.5 (%), and V1.0 (%)
for OSA subjects with AHI $5, AHI $15 and AHI .30. The
predictive parameters for V0.2 (%), V0.5 (%), and V1.0 (%) are
reported in Table 2. Interestingly, V1.0 (%) was the least
Figure 1 - Negative expiratory pressure (NEP) application during tidal expiration. Airflow and mouth pressure (Pm) during tidal
respiration and NEP application. The hatched areas under the flow curve measure the expired volume at 0.2 s (V0.2), 0.5 s (V0.5), and
1.0 s (V1.0) after NEP application. Insp: inspiration; Exp: expiration.
Table 1 - Anthropometric and respiratory data of the subjects arranged by AHI.
Variables
AHI ,5/h
(n = 29)
5# AHI ,15/h
(n = 28)
15# AHI #30/h
(n= 34)
AHI .30/h
(n= 64)
Age (y) 41¡12 56¡9* 53¡10* 53¡11*
BMI (kg/m2) 27.5¡3.5 29.9¡5.7 34.5¡7.71 35.1¡7.1*
Neck circumference (cm) 39.5¡2.8 40.2¡3.0 42.6¡3.61 43.7¡4.1*
AHI (events/h) 2.0¡1.4 9.1¡2.8* 21.4¡3.8* 61.1¡18.4*
FVC (% predicted) 100¡14 100¡14 99¡15 96¡18
FEV1 (% predicted) 105¡15 100¡15 99¡15 96¡8
FEF25-75 (% predicted) 96¡23 86¡27 88¡30 86¡28
BMI =body mass index; AHI = apnea-hypopnea index; FVC= forced vital capacity; FEV1 = forced expiratory volume in one second; FEF25-75 = forced
expiratory flow 25-75%.
Values are presented as the means¡SD.
*p,0.0001,
1p,0.005; healthy vs. OSA severity groups.
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effective volume parameter in distinguishing between
healthy and OSA subjects. V0.2 (%) identified subjects with
AHI $15 and .30 (i.e., moderate-to-severe OSA) with very
high sensitivity and identified subjects with an AHI ,5 (i.e.,
healthy subjects) with very high specificity. A negative test
result indicated 100% probability of having an AHI not
exceeding 30, 93.2% probability of having an AHI not
exceeding 15, but an equal probability of being healthy or
having mild OSA. A positive test result indicated 98%
probability of having an AHI $5, 84.8% probability of
having an AHI $15 and 56.1% probability of having an AHI
.30. Thus, the measurement of flow limitation using V0.2
(%), which was determined using NEP, was an effective
predictor of OSA.
The ROC curve analysis applied to the BMI measure-
ments showed that BMI was significantly less reliable
(p,0.007) than V0.2 (%) in discriminating OSA subjects.
The areas under the ROC curves for BMI and V0.2 (%) were
0.79 (95% CI: 0.72 to 0.85) and 0.91 (95% CI: 0.85 to 0.95),
respectively.
Figure 4 illustrates the relationship between AHI and V0.2
(%) graphically. The optimal cutoff point to discriminate
subjects with an AHI .30 was 23%, and only five subjects
with values of V0.2 lower than 23% (positive for OSA) were
healthy. No subject with a V0.2 value higher than 23%
(negative for OSA) had severe OSA. Only three subjects
with a V0.2 value higher than 23% had moderate OSA, and
15 subjects had mild OSA (1.9 and 9.6%, respectively).
DISCUSSION
The present study verified the efficacy of the flow
limitation induced by NEP and evaluated by V0.2 (%), V0.5
(%) and V1.0 (%) as a screening tool to detect OSA risk. Our
results indicated that the V0.2 (%) parameter is more sensitive
in detecting patients with moderate and severe OSA. V0.2 (%)
identified subjects with moderate and severe OSA with very
high sensitivity and identified healthy subjects with very
high specificity. When the NEP test was negative for OSA,
there was a high probability that the subject did not have
moderate or severe OSA. When the test was positive, most
OSA subjects (AHI $5) were identified. For a positive test,
the predictive value to identify OSA was very high, but the
predictive value for distinguishing severity was lower.
Conversely, a negative test was predictive of subjects who
did not have moderate and severe OSA. Thus, the measure-
ment of flow limitation by V0.2 (%) induced by NEP is a
valuable predictor for OSA and can reliably distinguish
between OSA and healthy subjects.
Obesity and increased upper airway collapsibility are
considered two of the most important determinants of OSA.
Previous studies regarding obese male subjects have shown
that at least 40% are affected by OSA.26-27 Because obesity is
considered to be a major cause of OSA, we compared the
ROC curve for V0.2 (%) induced by NEP to the ROC curve
for BMI to identify OSA subjects. The V0.2 (%) curve had
better discriminatory power than BMI, which agreed with
the supposition that collapsibility is the main mechanism of
upper airway obstruction during sleep.
It is important to heighten public awareness regarding the
potential hazards and health risks that surround untreated
sleep apnea.1-7,28-34 In addition, certain groups of indivi-
duals, such as commercial drivers, need to realize that OSA
is dangerous to them and to others. Physicians and the
general population are widely aware of the potentially
deleterious effects of OSA on an individual patient’s health
and wellbeing, and there is even increasing awareness
among public administrators of the traffic hazards and
accidents at work that are linked to untreated OSA. Many
patients who present for surgical procedures may have
undiagnosed OSA, despite an improved awareness and
increased frequency of diagnosis.29-31 Untreated OSA
patients are known to have higher incidences of difficult
intubation, postoperative complications, increased intensive
care unit admissions, and longer hospital stays.32 Several
case reports have documented an increase in the incidence
of postoperative complications and deaths among patients
suspected of having OSA.33-34 In previous studies, 24% of
patients with OSA had significant postoperative complica-
tions, compared with 9% of the patients in the control
Figure 2 - The relationships between AHI and V0.2 (%), V0.5 (%),
and V1.0 (%).
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Figure 3 - Expiratory volumes of each subject at 0.2, 0.5, and 1.0 s expressed as the % of the mean expiratory volume of the three
breaths preceding NEP application for healthy subjects and subjects from the 3 OSA severity groups. The means and SD are shown. NS:
not significant, *p,0.0001, 1p,0.003, #p,0.01; healthy vs. OSA severity groups.
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group.29,30 Identifying patients at risk for OSA is the first
step in preventing postoperative complications due to OSA.
Polysomnography is the gold standard for diagnosis of
OSA, but increasing awareness of the importance of
identifying patients with OSA has increased the waiting
lists for diagnosis and proper treatment. Nevertheless, it
would take several years to satisfy the current requirement
for polysomnography in the general population with
existing resources.35 The use of portable monitoring devices
for the diagnosis of OSA would probably not be sufficient to
overcome the growing demand for diagnostic testing.36
Although sleep recordings are mandatory for OSA diag-
nosis, it would be useful to identify simple, reliable and
inexpensive screening methods for physicians to detect
subjects who are more likely to be at risk for upper airway
obstruction.
A highly sensitive and positive predictive screening tool
with an acceptable specificity and negative predictive ability
is a basic requirement when screening patients for a disease
that has an important impact on health. OSA screening tests
have demonstrated considerable variability in predictive
ability, which depends on the screening tool, the patient
population, and the OSA severity. An OSA screening
questionnaire that was tested in patients from sleep centers
resulted in 70% to 93% sensitivity.37-41 Ross et al.42
published a meta-analysis of screening tests for OSA in
2000 and found that a lack of discriminatory analysis makes
it difficult to recommend an evidence-based choice of tests
for preoperative screening. In addition, the Berlin ques-
tionnaire41 has shown varied results that depend on the
patient population studied. For example, the sensitivity was
86% in primary care patients40 and 57-68% in sleep
laboratory patients.43
Previous studies have used different methods to evaluate
the flow limitation induced by NEP during wakefulness and
assess upper airway collapsibility in OSA and healthy
subjects.14-22 Some studies have applied methods that were
the same as those adopted for the evaluation of flow
limitation in patients with bronchial obstruction,14 whereas
others have introduced new methods to evaluate upper
airway obstruction.15-22 The various methods have demon-
strated that NEP can play a role in the identification of
upper airway flow limitation without reaching entirely
satisfactory discriminatory levels. Ferretti et al.21 evaluated
flow limitation by measuring the expiratory volume at 0.5
and 1.0 s after NEP application and concluded that the NEP
test appears to have a limited usefulness as a clinical tool for
routine screening. In addition, Van Meerhaeghe et al.17
expressed the expiratory flow limitation as the percentage of
the expired tidal volume over which the NEP-induced flow
did not exceed the spontaneous flow, and they concluded
that NEP may be useful in predicting OSA with AHI $15 in
a clinic-based population (the sensitivity was 81.9% and the
specificity was 69.1%). Tamisier et al.20 used the ratio
between the areas under the curves of the NEP flow-volume
loop and the spontaneous flow-volume loop and reported
that the quantitative index was higher in healthy subjects
than in patients with any type of breathing-related sleep
disorder (the predictive positive value was 96.6% and the
predictive negative value was 76.9%). Subjects with breath-
ing-related sleep disorders and healthy subjects exhibited
significant differences, there was a trend toward a lower
quantitative index in patients with severe OSA who
exhibited greater expression of a collapsible upper airway.
Subjects with mild OSA, however, were not included in this
study. In our study, we measured the expiratory volume
Table 2 - Receiver-operating characteristic curve analysis for NEP volume at V0.2, V0.5, and V1.0.
V0.2 V0.5 V1.0
AHI $5/h
Optimal cutoff point 22.2 71.0 127.4
Sensitivity, % 81.1 (73.2-87.5) 84.3 (76.7-90.1) 84.1 (76.6-90.0)
Specificity, % 93.1 (77.2-99.2) 89.7 (72.6-97.8) 82.8 (64.2-84.2)
PPV, % 98.1 (95.5-100) 97.3 (94.3-100) 95.5 (91.7-99.3)
NPV, % 52.9 (39.2-66.6) 56.5 (42.2-70.8) 54.5 (39.8-69.2)
Area under the ROC curve 0.91 (0.85-0.95) 0.90 (0.84-0.94) 0.88 (0.81-0.92)
AHI $15/h
Optimal cutoff point 22.9 69.8 108.7
Sensitivity, % 96.9 (91.3-99.4) 93.9 (87.1-97.7) 82.6 (73.7-89.6)
Specificity, % 70.7 (57.3-81.9) 74.1 (61.0-84.7) 79.0 (66.1-88.6)
PPV, % 84.8 (90.7-98.9) 86.0 (79.4-82.5) 86.2 (79.2-93.2)
NPV, % 93.2 (85.8-100) 87.8 (78.6-97.0) 72.6 (61.5-83.7)
Area under the ROC curve 0.90 (0.84-0.94) 0.90 (0.85-0.95) 0.90 (0.84-0.94)
AHI .30/h
Optimal cutoff point 23.0 69.1 93.8
Sensitivity, % 100 (94.4-100) 95.3 (86.9-99.0) 70.3 (57.6-81.1)
Specificity, % 45.6 (35.2-56.4) 51.1 (40.4-61.7) 71.4 (61.0-80.4)
PPV, % 56.1 (47.0-65.2) 57.5 (48.1-66.9) 70.3 (59.1-81.5)
NPV, % 100 (100-100) 94.0 (87.4-100) 71.7 (62.5-80.9)
Area under the ROC curve 0.78 (0.71-0.84) 0.79 (0.72-0.85) 0.78 (0.70-0.84)
Data are presented as the means (95% confidence interval).
AHI =Apnea-hypopnea index;
PPV=positive predictive value;
NPV=negative predictive value;
ROC= receiver operating characteristic;
V0.2 = volume for 200 ms after NEP application;
V0.5 = volume for 500 ms after NEP application;
V1.0 = volume for 1 s after NEP application.
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(expressed as the percent of the mean expiratory volume of
the three breaths preceding NEP application) at the very
beginning of expiration (V0.2), at 0.5 s (V0.5), and at 1.0 s
(V1.0) in a large sample of subjects and showed that V0.2 and
V0.5 were predictive of OSA (V1.0 was less useful). The NEP
test may provide an objective assessment to identify patients
at high risk for OSA and could be widely applied to reduce
socioeconomic impact of this disease.
This investigation was limited by the various anthropo-
metric characteristics of the different groups. In addition,
we only enrolled subjects who had attended a sleep
laboratory, and these subjects may not represent the general
population. Importantly, the present study included sub-
jects who represented the entire spectrum of disease
severity, which prevented the exaggeration of diagnostic
accuracy that could occur when a diagnostic test is
evaluated in a sample with a limited severity spectrum.44
In conclusion, the evaluation of flow limitation during
wakefulness using the NEP technique was predictive of
OSA. The NEP test was able to reliably discriminate
among subjects who had an AHI $5 and subjects who had
an AHI ,15. The NEP test could be adopted as a
screening test for the evaluation of suspected OSA
patients because it appears to be a very reliable diurnal
test that can objectively predict OSA. The NEP test may be
even more useful when combined with anamnestic data,
such as the symptoms of snoring and hypersomnolence.
Further studies should be performed to evaluate whether
OSA can be screened using NEP in the general popula-
tion. The measurement of flow limitation based on V0.2
(%) during wakefulness may be a very reliable method to
identify healthy subjects when the test is negative and
subjects with OSA when the test is positive. Further data
are required to determine the operating characteristics of
the technique for OSA screening in patients who are
awake.
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